

## Supporting Information

### **Molecular insights into Mmpl3 leads to the development of novel indole-2-carboxamides as antitubercular agents**

Rajdeep Ray<sup>[a]</sup>, Sumit Raosaheb Birangal<sup>[a]</sup>, Fajeelath Fathima<sup>[a]</sup>, Helena I. Boshoff<sup>[c]</sup>, Grace Forbes<sup>[c]</sup>, Raghu H. Chandrashekar<sup>[b]</sup>, Gautham G. Shenoy<sup>[a]\*</sup>

*[a] Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.*

*[b] Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India. Pin: 576104.*


*[c] Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA*

*\* Corresponding author; Corresponding author e-mail: gautham.gs@manipal.edu;*


## Contents

|                              |        |
|------------------------------|--------|
| 1. Figures and Tables.....   | III    |
| 2. $^1\text{H}$ NMR .....    | XXII   |
| 3. $^{13}\text{C}$ NMR ..... | XXVIII |
| 4. Mass Spectra.....         | XXXIII |

## Figures and Tables




(a)




(b)


Fig. S1. (a) Protein-ligand complex of MmpL3 and A12. (b) Protein-ligand complex of MmpL3 and A16. In the figures, the green coloured ball and stick structures represent the ligand, the grey coloured ball and stick structures represent the residues at the binding site, and the grey coloured surface signify the hydrophobic pocket formed by the non-polar residues at the binding site.




(a)




(b)



(c)




(d)




(e)


Fig. S2. (a) Protein-ligand complex of MmpL3 and 3a2T. (b) Protein-ligand complex of MmpL3 and 3a2'T. (c) Protein-ligand complex of MmpL3 and 3a2C. (d) Protein-ligand complex of MmpL3 and 3bC. (e) Protein-ligand complex of MmpL3 and 5eT. In the figures, the green coloured ball and stick structures represent the ligand, the grey coloured ball and stick structures represent the residues at the binding site, and the grey coloured surface signify the hydrophobic pocket formed by the non-polar residues at the binding site. 3a2T and 3a2'T represent the mirror image structures of the trans-isomeric forms of 3a. 3bC represents the cis-isomeric form of 3b and 5eT represent the trans-isomeric form of 5e.




(a)



(b)




(c)




(d)





(e)



(f)

Fig. S3. (a) Protein-ligand complex of MmpL3 and 5a. (b) Protein-ligand complex of MmpL3 and 5c. (c) Protein-ligand complex of MmpL3 and 5d. (d) Protein-ligand complex of MmpL3 and 5f. (e) Protein-ligand complex of MmpL3 and 5g. (f) Protein-ligand complex of MmpL3 and 5g. In the figures, the green coloured ball and stick structures represent the ligand, the grey

coloured ball and stick structures represent the residues at the binding site, and the grey coloured surface signify the hydrophobic pocket formed by the non-polar residues at the binding site.













Figure S4. Stereoisomers of synthesized molecules 3a, 3b, and 5e. Molecules were labelled according to their cis or trans forms and the R/S configurations of their chiral centres.


Table S1. Reported Indoles with their antitubercular activity.




| Compound Name   | MIC  | X | R | dG Bind | pMIC** |
|---|------|---|---|---------|--------|
| A3<br>( <i>N</i> -Cyclohexyl-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide) | 0.93 | - |   | -30.146 | 6.032  |
| A4<br>( <i>N</i> -Phenyl-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)     | 3.8  | - |   | -45.165 | 5.42   |

|  |       |   |  |         |       |
|--|-------|---|--|---------|-------|
| A5<br>( <i>N</i> -(3-Fluoro-4-methylphenyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)   | 1.7   | - |    | -49.617 | 5.77  |
| A6<br>( <i>N</i> -(4-Pyridinyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)               | 240   | - |     | -34.199 | 3.62  |
| A7<br>( <i>N</i> -(1-Methyl-4-piperidinyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)    | 448   | - |     | -61.306 | 3.349 |
| A8<br>( <i>N</i> -(1-Isopropyl-4-piperidinyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide) | 204   | - |   | -75.494 | 3.69  |
| A9<br>( <i>N</i> -(1-Methyl-4-azepanyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)       | 428   | - |  | -65.922 | 3.369 |
| A10<br>( <i>N</i> -Cyclopropyl-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)                | 561   | - |   | -33.608 | 3.251 |
| A11<br>( <i>N</i> -Cycloheptyl-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)                | 0.055 | - |   | -34.372 | 7.26  |
| A12<br>( <i>N</i> -Cyclooctyl-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)                 | 0.013 | - |   | -41.156 | 7.886 |
| A13<br>( <i>N</i> -(1-Adamantyl)-4,6-dimethyl-1 <i>H</i> -                                   | 0.012 | - |   | -24.645 | 7.921 |


|  |       |   |  |         |       |
|--|-------|---|--|---------|-------|
| <i>indole-2-carboxamide</i> )  |       |   |  |         |       |
| A14<br>( <i>N</i> -(2-Adamantyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)          | 0.012 | - |  | -41.459 | 7.921 |
| A15<br>( <i>N</i> -(Cyclohexylmethyl)-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide)     | 0.88  | - |  | -38.389 | 6.056 |
| A16<br>( <i>N</i> -Cyclohexyl- <i>N</i> ,4,6-trimethyl-1 <i>H</i> -indole-2-carboxamide) | 450   | - |  | -43.209 | 3.347 |
| A17<br>(4,6-Dimethyl-1 <i>H</i> -indol-2-yl)(piperidin-1-yl)methanone)                   | >499  | - |  | -31.34  | -     |
| A18<br>( <i>N</i> -Cyclohexyl-1,4,6-trimethyl-1 <i>H</i> -indole-2-carboxamide)          | 450   | - |  | -49.47  | 3.347 |




A19 - A25



A26 - A32, A35 - A36



















A33, A34









A37 - A40

| Compound Name  | MIC | X            | R | dG Bind (kcal/mol) | pMIC** |
|--|-----|--------------|---|--------------------|--------|
| A19<br>( <i>N</i> -Cycloheptyl-4,6-dimethylbenzofuran-2-carboxamide) | 56  | 4,6-dimethyl |   | -50.268            | 4.252  |


|   |      |              |  |                 |       |
|---|------|--------------|--|-----------------|-------|
| A20<br>( <i>N</i> -Cyclooctyl-4,6-dimethylbenzofuran-2-carboxamide)                   | 27   | 4,6-dimethyl |     | -51.655         | 4.569 |
| A21<br>( <i>N</i> -(1-Adamantyl)-4,6-dimethylbenzofuran-2-carboxamide)                | 3.1  | 4,6-dimethyl |    | -28.147         | 5.509 |
| A22*<br>( <i>N</i> -(Bicyclo[2.2.1]-2-heptanyl)-4,6-dimethylbenzofuran-2-carboxamide) | 113  | 4,6-dimethyl |     | -42.033/-38.269 | 3.94  |
| A23<br>( <i>N</i> -Hexyl-4,6-dimethylbenzofuran-2-carboxamide)                        | 59   | 4,6-dimethyl |    | -48.692         | 4.229 |
| A24<br>(5-Chloro- <i>N</i> -cyclooctylbenzofuran-2-carboxamide)                       | 26   | 5-Cl         |  | -43.748         | 4.585 |
| A25<br>(5-Chloro- <i>N</i> -(1-adamantyl)benzofuran-2-carboxamide)                    | ≥388 | 5-Cl         |  | -29.327         | -     |
| A26<br>( <i>N</i> -Cyclohexyl-1 <i>H</i> -indole-2-carboxamide)                       | >528 | H            |  | -33.358         | -     |
| A27<br>( <i>N</i> -(3-Fluoro-4-methylphenyl)-1 <i>H</i> -indole-2-carboxamide)        | 477  | H            |   | -40.193         | 3.321 |

|   |      |                           |   |         |       |
|---|------|---------------------------|---|---------|-------|
| A28<br>( <i>N</i> -Cycloheptyl-4,6-difluoro-1 <i>H</i> -indole-2-carboxamide)                         | 0.86 | 4,6-difluoro              |    | -44.001 | 6.066 |
| A29<br>( <i>N</i> -Cyclooctyl-4,6-difluoro-1 <i>H</i> -indole-2-carboxamide)                          | 0.1  | 4,6-difluoro              |    | -41.929 | 7     |
| A30<br>( <i>N</i> -(1-Adamantyl)-6-methoxy-1 <i>H</i> -indole-2-carboxamide)                          | 0.77 | 6-OCH <sub>3</sub>        |    | -23.084 | 6.114 |
| A31<br>( <i>N</i> -(1-Adamantyl)-5-chloro-1 <i>H</i> -indole-2-carboxamide)                           | 0.38 | 5-Cl                      |   | -22.11  | 6.42  |
| A32<br>( <i>N</i> -(1-Adamantyl)-6-hydroxy-1 <i>H</i> -indole-2-carboxamide)                          | 13   | 6-OH                      |  | -22.848 | 4.886 |
| A33<br>( <i>N</i> -Cyclooctyl-6-methoxy-1 <i>H</i> -pyrrolo[3,2- <i>c</i> ]pyridine-2-carboxamide)    | 6.6  | -                         |  | -38.97  | 5.18  |
| A34<br>( <i>N</i> -(1-Adamantyl)-6-methoxy-1 <i>H</i> -pyrrolo[3,2- <i>c</i> ]pyridine-2-carboxamide) | 1.5  | -                         |  | -25.807 | 5.824 |
| A35<br>( <i>N</i> -Cycloheptyl-4,6-bis(trifluoromethyl)-1 <i>H</i> -indole-2-carboxamide)             | 0.64 | 4,6-bis(CF <sub>3</sub> ) |  | -54.878 | 6.194 |


|  |      |                           |   |         |       |
|--|------|---------------------------|---|---------|-------|
| A36<br>( <i>N</i> -Cyclooctyl-4,6-bis(trifluoromethyl)-1 <i>H</i> -indole-2-carboxamide)   | 0.04 | 4,6-bis(CF <sub>3</sub> ) |    | -56.092 | 7.398 |
| A37<br>( <i>N</i> -Cycloheptyl-4,6-dimethyl-1 <i>H</i> -benzo[d]imidazole-2-carboxamide)   | >224 | -                         |    | -20.23  | -     |
| A38<br>( <i>N</i> -Cyclooctyl-4,6-dimethyl-1 <i>H</i> -benzo[d]imidazole-2-carboxamide)    | 1.7  | -                         |    | -44.297 | 5.77  |
| A39<br>( <i>N</i> -(1-Adamantyl)-4,6-dimethyl-1 <i>H</i> -benzo[d]imidazole-2-carboxamide) | 0.39 | -                         |  | -26.591 | 6.409 |
| A40<br>( <i>N</i> -(2-Adamantyl)-4,6-dimethyl-1 <i>H</i> -benzo[d]imidazole-2-carboxamide) | 1.5  | -                         |  | -56.236 | 5.824 |




B3-B39











B40-B41
















B42

| Compound Name   | MIC   | X             | R   | dG Bind (kcal/mol) | pMIC** |
|---|-------|---------------|---|--------------------|--------|
| B3<br>( <i>N</i> -Cyclohexyl-4,6-dimethyl-1 <i>H</i> -indole-2-carboxamide) | 0.013 | 4, 6-dimethyl |  | -44.645            | 7.886  |








|  |      |          |  |         |       |
|--|------|----------|--|---------|-------|
| B4<br>( <i>N</i> -Cycloheptyl-4-methyl-1 <i>H</i> -indole-2-carboxamide) | 0.93 | 4-methyl |    | -51.154 | 6.032 |
| B5<br>( <i>N</i> -Cyclooctyl-4-methyl-1 <i>H</i> -indole-2-carboxamide)  | 0.11 | 4-methyl |    | -46.943 | 6.959 |
| B6<br>(4-Amino- <i>N</i> -cyclooctyl-1 <i>H</i> -indole-2-carboxamide)   | 20   | 4-amino  |    | -39.861 | 4.699 |
| B7<br>( <i>N</i> -Cycloheptyl-5-methyl-1 <i>H</i> -indole-2-carboxamide) | 7.4  | 5-methyl |   | -40.691 | 5.131 |
| B8<br>( <i>N</i> -Cyclooctyl-5-methyl-1 <i>H</i> -indole-2-carboxamide)  | 0.88 | 5-methyl |  | -40.691 | 6.056 |
| B9<br>(5-Amino- <i>N</i> -cyclooctyl-1 <i>H</i> -indole-2-carboxamide)   | 80   | 5-amino  |  | -41.406 | 4.097 |
| B10<br>( <i>N</i> -Cyclooctyl-6-methyl-1 <i>H</i> -indole-2-carboxamide) | 0.11 | 6-methyl |  | -41.571 | 6.959 |
| B11<br>(6-Bromo- <i>N</i> -cyclooctyl-1 <i>H</i> -indole-2-carboxamide)  | 0.09 | 6-Br     |  | -43.103 | 7.046 |



|   |       |               |  |         |       |
|---|-------|---------------|--|---------|-------|
| B12<br>( <i>N</i> -(1-Adamantanyl)-6-bromo-1 <i>H</i> -indole-2-carboxamide)  | 0.042 | 6-Br          |     | -15.74  | 7.377 |
| B13<br>(6-Bromo- <i>N</i> -((1 <i>R</i> ,2 <i>R</i> ,3 <i>R</i> ,5 <i>S</i> )-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1 <i>H</i> -indole-2-carboxamide) | 0.01  | 6-Br          |    | -31.287 | 8     |
| B14<br>( <i>N</i> -Cycloheptyl-7-methyl-1 <i>H</i> -indole-2-carboxamide)   | 30    | 7-methyl      |     | -40.826 | 4.523 |
| B15<br>( <i>N</i> -Cyclooctyl-7-methyl-1 <i>H</i> -indole-2-carboxamide)  | 3.5   | 7-methyl      |   | -43.09  | 5.456 |
| B16<br>( <i>N</i> -Cycloheptyl-5,7-dimethyl-1 <i>H</i> -indole-2-carboxamide)   | 3.5   | 5,7-dimethyl  |  | -15.214 | 5.456 |
| B17<br>( <i>N</i> -Cyclooctyl-5,7-dimethyl-1 <i>H</i> -indole-2-carboxamide)  | 0.21  | 5,7-dimethyl  |  | -44.387 | 6.678 |
| B18<br>( <i>N</i> -Cycloheptyl-4,6-dimethoxy-1 <i>H</i> -indole-2-carboxamide)  | 3.2   | 4,6-dimethoxy |  | -41.776 | 5.495 |

|  |       |               |  |                 |       |
|--|-------|---------------|--|-----------------|-------|
| B19<br>( <i>N</i> -Cyclooctyl-4,6-dimethoxy-1 <i>H</i> -indole-2-carboxamide)  | 0.19  | 4,6-dimethoxy |    | -46.65          | 6.721 |
| B20<br>(4,6-Dichloro- <i>N</i> -cyclooctyl-1 <i>H</i> -indole-2-carboxamide)   | 0.011 | 4,6-dichloro  |    | -48.404         | 7.959 |
| B21<br>( <i>N</i> -(1-Adamantanyl)-4,6-dichloro-1 <i>H</i> -indole-2-carboxamide)  | 0.011 | 4,6-dichloro  |    | -29.464         | 7.959 |
| B22*<br>( <i>N</i> -( <i>exo</i> -Bicyclo[2.2.1]heptan-2-yl)-4,6-dichloro-1 <i>H</i> -indole-2-carboxamide)  | 0.39  | 4,6-dichloro  |   | -42.033/-38.269 | 6.409 |
| B23<br>(4,6-Dichloro- <i>N</i> -( <i>endo</i> -(1 <i>R</i> )-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)-1 <i>H</i> -indole-2-carboxamide)                       | 0.043 | 4,6-dichloro  |  | -41.988         | 7.367 |
| B24<br>(4,6-Dichloro- <i>N</i> -((1 <i>R</i> ,2 <i>R</i> ,3 <i>R</i> ,5 <i>S</i> )-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1 <i>H</i> -indole-2-carboxamide) | 0.021 | 4,6-dichloro  |  | -45.39          | 7.678 |

|   |       |              |  |         |       |
|---|-------|--------------|--|---------|-------|
| B25<br>(4,6-Dichloro-<br>N-<br>(1 <i>S</i> ,2 <i>S</i> ,3 <i>S</i> ,5 <i>R</i> )-<br>2,6,6-<br>trimethylbicyclo<br>[3.1.1]-<br>heptan-3-yl)-<br>1 <i>H</i> -indole-2-<br>carboxamide) | 0.086 | 4,6-dichloro |  | -60.342 | 7.066 |
| B26<br>(4,6-Difluoro-N-<br>(1 <i>R</i> ,2 <i>R</i> ,3 <i>R</i> ,5 <i>S</i> )-<br>2,6,6-<br>trimethylbicyclo<br>[3.1.1]-<br>heptan-3-yl)-<br>1 <i>H</i> -indole-2-<br>carboxamide)     | 0.012 | 4,6-difluoro |  | -45.298 | 7.96  |
| B27<br>(4,6-Difluoro-N-<br>(1 <i>S</i> ,2 <i>S</i> ,3 <i>S</i> ,5 <i>R</i> )-<br>2,6,6-<br>trimethylbicyclo<br>[3.1.1]-<br>heptan-3-yl)-<br>1 <i>H</i> -indole-2-<br>carboxamide)     | 0.19  | 4,6-difluoro |  | -50.138 | 6.721 |
| B28<br>(4,6-Dichloro-<br>N-heptyl-1 <i>H</i> -<br>indole-2-<br>carboxamide)   | >300  | 4,6-dichloro |  | -54.412 | -     |
| B29<br>(4,6-Dichloro-<br>N-octyl-1 <i>H</i> -<br>indole-2-<br>carboxamide)  | >300  | 4,6-dichloro |  | -54.955 | -     |
| B30<br>( <i>E</i> )-4,6-<br>Dichloro-N-<br>(3,7-<br>dimethylocta-<br>2,6-dien-1-yl)-<br>1 <i>H</i> -indole-2-<br>Carboxamide)   | 11    | 4,6-dichloro |  | -56.552 | 4.959 |

|  |       |              |  |         |       |
|--|-------|--------------|--|---------|-------|
| B31<br>( <i>E</i> )- <i>N</i> -(3,7-Dimethylocta-2,6-dien-1-yl)-4,6-difluoro-1 <i>H</i> -indole-2-carboxamide)                       | >192  | 4,6-difluoro |    | -61.277 | –     |
| B32<br>(4,6-Dichloro- <i>N</i> -[ <i>(1R,2R,5R)</i> -6,6-dimethylbicyclo[3.1.1]heptan-2-yl)methyl]-1 <i>H</i> -indole-2-carboxamide) | 175   | 4,6-dichloro |    | -43.342 | 3.757 |
| B33<br>( <i>R</i> )- <i>N</i> -(1-Cyclohexylethyl)-4,6-dichloro-1 <i>H</i> -indole-2-carboxamide)                                    | 5.9   | 4,6-dichloro |    | -57.106 | 5.229 |
| B34<br>( <i>R</i> )- <i>N</i> -(1-Cyclohexylethyl)-4,6-difluoro-1 <i>H</i> -indole-2-carboxamide)                                    | 13    | 4,6-difluoro |  | -48.334 | 4.886 |
| B35<br>(4,6-Dichloro- <i>N</i> -(2,3-dihydro-1 <i>H</i> -inden-2-yl)-1 <i>H</i> -indole-2-carboxamide)                               | 0.72  | 4,6-dichloro |  | -48.526 | 6.143 |
| B36<br>( <i>N</i> -4,6-Difluoro-(2,3-dihydro-1 <i>H</i> -inden-2-yl)-1 <i>H</i> -indole-2-carboxamide)                               | 102   | 4,6-difluoro |   | -46.618 | 3.991 |
| B37<br>(4,6-Dichloro- <i>N</i> -(spiro[5.5]undecan-3-yl)-1 <i>H</i> -indole-2-carboxamide)   | 0.005 | 4,6-dichloro |  | -61.671 | 8.301 |

|   |       |                    |  |                 |       |
|---|-------|--------------------|--|-----------------|-------|
| B38<br>(4,6-Difluoro-N-(spiro[5.5]undecan-3-yl)-1H-indole-2-carboxamide)                  | 0.003 | 4,6-difluoro       |  | -57.453         | 8.523 |
| B39*<br>(4,6-Dichloro-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indole-2-carboxamide) | 10.9  | 4,6-dichloro       |  | -75.972/-69.899 | 4.963 |
| B40<br>(N-[(4,6-Dimethyl-1H-indol-2-yl)methyl]-Cycloheptanecarboxamide)                   | 54    | 4,6-dimethyl       |  | -54.502         | 4.268 |
| B41<br>(N-[(4,6-Dimethyl-1H-indol-2-yl)methyl]cyclooctylamine)                            | 0.31  | 4,6-dimethyl       |  | -73.543         | 6.509 |
| B42<br>(N-[6-(Trifluoromethoxy)benzothiazol-2-yl]-Cycloheptanecarboxamide)                | >300  | 5-trifluoromethoxy |  | -50.598         | -     |

Note: \* mixture of isomeric forms; \*\*pMIC= -log(10<sup>-6</sup> X MIC);

Table S2. Calculation of Standard Deviation and Standard Error of MMGBSA dG bind of B38.

| Sl No. | Compound Name | MD Time scale | Ensemble Average dG bind (kcal/mol) from MD snapshots | No. of snapshots | dG bind (kcal/mol) from minimized (docked) complex | Standard Deviation (kcal/mol) | Standard Error (kcal/mol) |
|--------|---------------|---------------|---|------------------|--|-------------------------------|---------------------------|
| 1      | B38           | 25 ns         | -57.457   | 24               | -57.453  | 0.239                         | 0.107                     |
| 2      |               | 25 ns         | -57.138   | 16               |  |                               |                           |
| 3      |               | 25 ns         | -57.694   | 30               |  |                               |                           |
| 4      |               | 25 ns         | -57.108   | 40               |  |                               |                           |
| 5      |               | 25 ns         | -57.556   | 40               |  |                               |                           |

### <sup>1</sup>H NMR




Figure S5: <sup>1</sup>H NMR of 3a in CDCl<sub>3</sub>. Splitting of peaks at 2.61 to 2.57 ppm and at 1.24 to 1.19 ppm is due to isomeric mixture of 3a.




Figure S6:  $^1\text{H}$  NMR of **3b** in  $\text{CDCl}_3$ . Splitting of proton peaks into two at 6.21 to 6.19 ppm, 4.35 to 4.32 ppm, 2.60 to 2.55 ppm and 1.17 to 1.12 ppm is due to presence of isomeric mixture of **3b**.




Figure S7:  $^1\text{H}$  NMR of **5a** in DMSO.




Figure S8: <sup>1</sup>H NMR of 5b in DMSO.




Figure S9: <sup>1</sup>H NMR of 5c in DMSO.






Figure S10:  $^1\text{H}$  NMR of 5d in DMSO.




Figure S11:  $^1\text{H}$  NMR of 5e in DMSO.




Figure S12:  $^1\text{H}$  NMR of 5f in DMSO.




Figure S13:  $^1\text{H}$  NMR of 5g in DMSO.




Figure S14: <sup>1</sup>H NMR of 5h in CDCl<sub>3</sub>.




Figure S15: <sup>1</sup>H NMR of intermediate 2 in DMSO. <sup>1</sup>H NMR (400 Mhz, DMSO-d) δ 12.887 (s, 1H), 11.36 (s, 1H), 7.63 (d, J = 8 Hz, 1H), 7.39 (d, J = 8, 1H), 7.24 (t, J = 7.4, 1H), 7.049 (t, J = 7.4, 1H), 2.53 (s, 3H).




Figure S16:  $^1\text{H}$  NMR of intermediate 4 in DMSO.  $^1\text{H}$  NMR (400 Mhz, DMSO- $d_6$ )  $\delta$  11.50 (s, 1H), 8.17 (d,  $J = 8$ , 1H), 7.59 (d,  $J = 8$  Hz, 1H), 7.41 (d,  $J = 8.4$  Hz, 1H), 7.16 (t,  $J = 7.4$  Hz, 1H), 7.02 (t,  $J = 7.6$ , 1H), 3.78 (m, 1H), 1.85 – 1.74 (m, 4H), 1.62 (d,  $J = 12.8$ , 2H), 1.38 – 1.27 (m, 4H), 1.18 – 1.15 (m, 1H)

### $^{13}\text{C}$ NMR




Figure S17:  $^{13}\text{C}$  NMR of 3a in DMSO. Splitting of peaks caused due to the presence of trans and cis-isomeric forms of 3a.




Figure S18:  $^{13}\text{C}$  NMR of 3b in DMSO. Splitting of peaks caused due to the presence of trans and cis-isomeric forms of 3b.




Figure S19:  $^{13}\text{C}$  NMR of 5a in DMSO.




Figure S20:  $^{13}\text{C}$  NMR of 5b in DMSO.




Figure S21:  $^{13}\text{C}$  NMR of 5c in  $\text{CDCl}_3$ .




Figure S22:  $^{13}\text{C}$  NMR of 5d in  $\text{CDCl}_3$ .




Figure S23:  $^{13}\text{C}$  NMR of 5e in  $\text{CDCl}_3$ .




Figure S24:  $^{13}\text{C}$  NMR of 5f in  $\text{CDCl}_3$ .




Figure S25:  $^{13}\text{C}$  NMR of 5g in  $\text{CDCl}_3$ .






Figure S26:  $^{13}\text{C}$  NMR of 5h in DMSO.

## Mass Spectra




Figure S27: M.S. of 3a




Figure S28: M.S. of 3b




Figure S29: M.S. of 5a




Figure S30: M.S. of 5b




Figure S31: M.S. of 5c




Figure S32: M.S. of 5d




Figure S33: M.S. of 5e




Figure S34: M.S. of 5f




Figure S35: M.S. of 5g




Figure S36: M.S. of 5h

